Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
Alessandro Pezzutto, Vittorio Sirolli, Lorenzo Di Liberato, Manrico Morroni, Mario Bonomini
Background: Immunoglobulin A deficiency (IgAD) is the most common form of primary immunodeficiency in western countries. It can be associated with the development of autoimmune diseases both in adults and in children even though the exact pathophysiology is not fully defined. Case Presentation: We report here a case of a young patient who developed nephrotic syndrome secondary to membranoproliferative glomerulonephritis associated with the incidental finding of IgAD...
2021: International Medical Case Reports Journal
#22
JOURNAL ARTICLE
Panagiotis Garantziotis, Stavros A P Doumas, Ioannis Boletis, Eleni Frangou
Despite improvements in understanding the pathogenic mechanisms of primary glomerular diseases, therapy still remains nonspecific. We sought to identify novel therapies targeting kidney-intrinsic injury of distinct primary glomerulonephritides through computational systems biology approaches. We defined the unique transcriptional landscape within kidneys from patients with focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), immunoglobulin A nephropathy (IgAN), membranous nephropathy (MN) and thin basement membrane nephropathy (TBMN)...
May 24, 2021: Journal of Clinical Medicine
#23
REVIEW
Laura De Souza, Janelle Prunster, Doris Chan, Aron Chakera, Wai H Lim
PURPOSE OF REVIEW: This review will provide a practical approach in the assessment of kidney failure patients with primary glomerulonephritides (GN) being considered for kidney transplantation, focusing on high-risk subtypes of immunoglobulin A nephropathy, focal segmental glomerulosclerosis, idiopathic membranous glomerulonephritis and membranoproliferative glomerulonephritis. RECENT FINDINGS: Recurrent glomerulonephritis remains one of the most common causes of allograft loss in kidney transplant recipients...
August 1, 2021: Current Opinion in Organ Transplantation
#24
JOURNAL ARTICLE
Pantelis Sarafidis, Alberto Ortiz, Charles J Ferro, Jean-Michel Halimi, Reinhold Kreutz, Francesca Mallamaci, Giuseppe Mancia, Christoph Wanner
Chronic kidney disease (CKD) is a major issue of public health. Hypertension control and use of renin--angiotensin system (RAS) blockers are the cornerstones of treatment for CKD of any cause. However, even under optimal RAS blockade, many individuals will progress towards more advanced CKD. Within the past few years, evidence from cardiovascular outcome trials with sodium--glucose co-transporter-2 (SGLT-2) inhibitors clearly suggested that these agents substantially delay CKD progression in patients with diabetes mellitus on top of standard-of-care treatment...
June 1, 2021: Journal of Hypertension
#25
JOURNAL ARTICLE
Fernando Javier Salazar-Torres, Miguel Medina-Perez, Zesergio Melo, Claudia Mendoza-Cerpa, Raquel Echavarria
Metabolic alterations serve a significant role in the pathogenesis of kidney disease. Long non-coding RNA (lncRNA) taurine upregulated gene 1 (TUG1) is a known regulator of podocyte health and mitochondrial biogenesis. Although TUG1 protects against podocyte loss in models of diabetic nephropathy, it is unknown if urinary TUG1 expression is associated with clinical and histopathological findings in non-diabetic patients diagnosed with glomerulonephritides. In the present study, the expression of TUG1, podocyte-specific markers (nephrin and podocin) and mitochondrial biogenesis-associated mRNAs (transcription factor A mitochondrial, cytochrome C oxidase subunit 5A and peroxisome proliferator-activated receptor γ coactivator 1α) were examined in urinary sediment of non-diabetic patients with biopsy-confirmed glomerulonephritides and healthy controls...
January 2021: Biomedical Reports
#26
RANDOMIZED CONTROLLED TRIAL
David C Wheeler, Bergur V Stefánsson, Niels Jongs, Glenn M Chertow, Tom Greene, Fan Fan Hou, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, Robert D Toto, C David Sjöström, Anna Maria Langkilde, Hiddo J L Heerspink
BACKGROUND: Dapagliflozin reduces the risk of kidney failure and heart failure in patients with chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney, cardiovascular, and mortality outcomes according to presence or absence of type 2 diabetes and according to underlying cause of chronic kidney disease, reported as diabetic nephropathy, chronic glomerulonephritides, ischaemic or hypertensive chronic kidney disease, or chronic kidney disease of other or unknown cause...
January 2021: Lancet Diabetes & Endocrinology
#27
REVIEW
Sarah Gleeson, Liz Lightstone
Nephrologists are routinely involved in the care of pregnant women with glomerulonephritis. Prepregnancy counseling is vital to inform women of the potential risks of pregnancy and to reduce those risks by optimizing clinical status and medications. In general, for all glomerulonephritides, the best pregnancy outcomes are achieved when the disease is in remission and the woman has preserved renal function with no proteinuria or hypertension. Each glomerulonephritis has specific considerations, for example in lupus nephritis, mycophenolate is teratogenic and must be stopped at least 6 weeks before conception, hydroxychloroquine is recommended for all pregnant women, and flares are frequently encountered and must be treated appropriately...
November 2020: Advances in Chronic Kidney Disease
#28
REVIEW
Mattia Zappa, Chiara Salviani, Mario Gaggiotti, Federico Alberici, Francesco Scolari
In the last decades there have been important changes in the epidemiology and natural history of bacterial infection-related glomerulonephritides. Once defined as an infancy-onset acute nephritic syndrome following a streptococcal infection, and characterized by a relative benign course, infection-related glomerulonephritis nowadays also affects the adult population, particularly the elderly and the chronically ill. The infectious agents and infection sites have become more diversified, and the prognosis is burdened by a higher rate of mortality, chronic kidney disease, end-stage renal disease and acute overload complications...
December 7, 2020: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
#29
JOURNAL ARTICLE
Fabio Sallustio, Claudia Curci, Nada Chaoul, Giulia Fontò, Gabriella Lauriero, Angela Picerno, Chiara Divella, Vincenzo Di Leo, Maria De Angelis, Sanae Ben Mkaddem, Luigi Macchia, Anna Gallone, Renato C Monteiro, Francesco Pesce, Loreto Gesualdo
BACKGROUND: Immunoglobulin A nephropathy (IgAN) is the most frequent primary glomerulonephritis. The role of the microbiota and mucosal immunity in the pathogenesis of IgAN remains a key element. To date, the hypothetical relationship between commensal bacteria, elevated tumour necrosis factor (TNF) superfamily member 13 [also known as B-cell activating factor (BAFF)] levels, perturbed homoeostasis of intestinal-activated B cells and intestinal IgA class switch has not been clearly shown in IgAN patients...
February 20, 2021: Nephrology, Dialysis, Transplantation
#30
JOURNAL ARTICLE
Vincenzo L'Imperio, Virginia Brambilla, Giorgio Cazzaniga, Franco Ferrario, Manuela Nebuloni, Fabio Pagni
Whole-slide imaging and virtual microscopy are useful tools implemented in the routine pathology workflow in the last 10 years, allowing primary diagnosis or second-opinions (telepathology) and demonstrating a substantial role in multidisciplinary meetings and education. The regulatory approval of this technology led to the progressive digitalization of routine pathological practice. Previous experiences on renal biopsies stressed the need to create integrate networks to share cases for diagnostic and research purposes...
June 2021: Journal of Nephrology
#31
JOURNAL ARTICLE
Giuseppe Coppolino, Nicola Comi, Davide Bolignano, Gemma Patella, Alessandro Comi, Michele Provenzano, Laura Rivoli, Michele Andreucci, Giorgio Fuiano
Objective: Available biomarkers for monitoring primary glomerulonephritides (GNs), often lack the ability to assess longitudinal changes and have great variability with poor sensitivity. Accruing evidence has demonstrated that Neutrophil Gelatinase-Associated Lipocalin (NGAL), holds promising capacities in predicting renal function worsening in various renal diseases. We aimed at analyzing urinary NGAL (uNGAL) levels in a cohort of individuals with biopsy-proven GNs in order to evaluate its ability to reflect the entity of renal damage and to predict disease evolution overtime...
2020: Frontiers in Cell and Developmental Biology
#32
JOURNAL ARTICLE
Kyriaki Kolovou, Katerina Laskari, Maria Roumelioti, Maria G Tektonidou, Panayiotis Panayiotidis, John N Boletis, Smaragdi Marinaki, Petros P Sfikakis
B-cell clonal expansion has been sporadically described in the blood and/or renal tissue of patients with glomerulonephritides, albeit with unclear pathogenetic role. Herein, using spectratyping analysis, we observed oligoclonal intrarenal B-cell populations in 59% of glomerulonephritis patients with podocyte injury (6/7 with focal segmental glomerulosclerosis, 1/3 minimal change disease, 1/3 idiopathic membranous nephropathy, 3/4 IgA nephropathy, 2/5 membranous lupus nephritis), 20% of glomerulonephritis patients without podocyte involvement (4/13 with mesangial or proliferative lupus nephritis, 0/3 idiopathic membranoproliferative glomerulonephritis, 0/4 pauci-immune vasculitis) and 17% of control patients with renal cancer...
August 2020: Clinical Immunology: the Official Journal of the Clinical Immunology Society
#33
JOURNAL ARTICLE
Anas AlYousef, Ali AlSahow, Bassam AlHelal, Ahmed Alqallaf, Emad Abdallah, Mohammed Abdellatif, Hani Nawar, Riham Elmahalawy
BACKGROUND: Glomerulonephritides (GN) are relatively rare kidney diseases with substantial morbidity and mortality. They are often difficult to treat, sometimes with no cure, and can lead to chronic kidney disease (CKD) and end stage kidney disease (ESKD). Kidney biopsy is the diagnostic procedure of choice with variable indications from center to center. It helps in identifying the exact specific diagnosis, assessing the level of disease activity and severity, and hence aids in proper therapy and helps predicting prognosis...
May 18, 2020: BMC Nephrology
#34
MULTICENTER STUDY
Ryohei Yamamoto, Enyu Imai, Shoichi Maruyama, Hitoshi Yokoyama, Hitoshi Sugiyama, Kosaku Nitta, Tatsuo Tsukamoto, Shunya Uchida, Asami Takeda, Toshinobu Sato, Takashi Wada, Hiroki Hayashi, Yasuhiro Akai, Megumu Fukunaga, Kazuhiko Tsuruya, Kosuke Masutani, Tsuneo Konta, Tatsuya Shoji, Takeyuki Hiramatsu, Shunsuke Goto, Hirofumi Tamai, Saori Nishio, Arimasa Shirasaki, Kojiro Nagai, Kunihiro Yamagata, Hajime Hasegawa, Hideo Yasuda, Shizunori Ichida, Tomohiko Naruse, Tomoya Nishino, Hiroshi Sobajima, Satoshi Tanaka, Toshiyuki Akahori, Takafumi Ito, Yoshio Terada, Ritsuko Katafuchi, Shouichi Fujimoto, Hirokazu Okada, Eiji Ishimura, Junichiro J Kazama, Keiju Hiromura, Tetsushi Mimura, Satoshi Suzuki, Yosuke Saka, Tadashi Sofue, Yusuke Suzuki, Yugo Shibagaki, Kiyoki Kitagawa, Kunio Morozumi, Yoshiro Fujita, Makoto Mizutani, Takashi Shigematsu, Naoki Kashihara, Hiroshi Sato, Seiichi Matsuo, Ichiei Narita, Yoshitaka Isaka
BACKGROUND: Despite recent advances in immunosuppressive therapy for patients with primary nephrotic syndrome, its effectiveness and safety have not been fully studied in recent nationwide real-world clinical data in Japan. METHODS: A 5-year cohort study, the Japan Nephrotic Syndrome Cohort Study, enrolled 374 patients with primary nephrotic syndrome in 55 hospitals in Japan, including 155, 148, 38, and 33 patients with minimal change disease (MCD), membranous nephropathy (MN), focal segmental glomerulosclerosis (FSGS), and other glomerulonephritides, respectively...
June 2020: Clinical and Experimental Nephrology
#35
REVIEW
Theodoros Ntrinias, Marios Papasotiriou, Lamprini Balta, Dimitra Kalavrizioti, Sotirios Vamvakas, Evangelos Papachristou, Dimitrios S Goumenos
The traditional chronic kidney disease (CKD) biomarkers (eGFR based on serum creatinine, sex and age and albuminuria) cannot predict a patient's individual risk for developing progressive CKD. For this reason, it is necessary to identify novel CKD biomarkers that will be able to predict which patients are prone to develop progressive disease and discriminate between disease processes in different parts of the nephron (glomeruli or tubules). A good biomarker should change before or simultaneously with lesion development and its changes should correlate strongly with lesion development...
December 1, 2019: Prilozi (Makedonska Akademija Na Naukite i Umetnostite. Oddelenie za Medicinski Nauki)
#36
REVIEW
Adrián M Ramos, Beatriz Fernández-Fernández, María Vanessa Pérez-Gómez, Sol María Carriazo Julio, María Dolores Sanchez-Niño, Ana Sanz, Marta Ruiz-Ortega, Alberto Ortiz
Introduction : Chronic kidney disease (CKD) is characterized by increased risks of progression to end-stage kidney disease requiring dialysis and cardiovascular mortality, predicted to be among the five top causes of death by 2040. Only the design and optimization of novel strategies to develop new drugs to treat CKD will contain this trend. Current therapy for CKD includes nonspecific therapy targeting proteinuria and/or hypertension and cause-specific therapies for diabetic kidney disease, autosomal dominant polycystic kidney disease, glomerulonephritides, Fabry nephropathy, hemolytic uremic syndrome and others...
January 2020: Expert Opinion on Drug Discovery
#37
JOURNAL ARTICLE
Wei Wang, Yuanmeng Yu, Jiqiu Wen, Mingchao Zhang, Jinsong Chen, Dongrui Cheng, Longjiang Zhang, Zhihong Liu
BACKGROUND AND OBJECTIVES: Recent developments indicated that functional magnetic resonance imaging (MRI) could potentially provide noninvasive assessment of kidney interstitial fibrosis in patients with kidney diseases, but direct evidence from histopathology is scarce. We aimed to explore the diagnostic utilities of functional MRI for the evaluation of kidney allograft interstitial fibrosis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We prospectively examined 103 kidney transplant recipients who underwent for-cause biopsies and 20 biopsy-proven normal subjects with functional MRI...
September 6, 2019: Clinical Journal of the American Society of Nephrology: CJASN
#38
REVIEW
Anjali A Satoskar, Samir V Parikh, Tibor Nadasdy
For over a century, acute 'post-streptococcal glomerulonephritis' (APSGN) was the prototypical form of bacterial infection-associated glomerulonephritis, typically occurring after resolution of infection and a distinct infection-free latent period. Other less common forms of infection-associated glomerulonephritides resulted from persistent bacteraemia in association with subacute bacterial endocarditis and shunt nephritis. However, a major paradigm shift in the epidemiology and bacteriology of infection-associated glomerulonephritides has occurred over the past few decades...
January 2020: Nature Reviews. Nephrology
#39
JOURNAL ARTICLE
Francesca Conserva, Mariagrazia Barozzino, Francesco Pesce, Chiara Divella, Annarita Oranger, Massimo Papale, Fabio Sallustio, Simona Simone, Luigi Laviola, Francesco Giorgino, Anna Gallone, Paola Pontrelli, Loreto Gesualdo
Diabetic Nephropathy (DN) is a chronic complication of diabetes and the primary cause of end stage renal disease. Differential diagnosis for DN requires invasive histological investigation, thus there is need for non-invasive biomarkers to discriminate among different histological lesions in diabetic patients. With the aim to identify a pattern of differentially expressed miRNAs in kidney biopsies of DN patients, we assayed miRNA expression in kidney biopsies from DN patients, diabetic patients with membranous nephropathy and patients with normal histology...
August 6, 2019: Scientific Reports
#40
JOURNAL ARTICLE
Anca Roxana Hirja, Luminita Voroneanu, Dimitrie Siriopol, Ionut Nistor, Simona Hogas, Mugurel Apetrii, Carmen Volovat, Gabriel Veisa, Irina Luanda Mititiuc, Laura Florea, Mihai Onofriescu, Adrian Covic
BACKGROUND: The treatment of most glomerulonephritides is still based on a combination of an oral corticosteroid and an alkylating agent, with favorable outcomes, but with serious side effects. The objective of this study was to reduce the cumulative corticosteroid dose in patients with high risk of corticosteroid-related adverse events by replacing daily oral corticosteroids with intravenous (iv) methylprednisolone pulses, associated with monthly pulse i.v. cyclophosphamide (according to KDIGO guidelines) in patients with glomerulonephritis...
October 2019: International Urology and Nephrology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
